Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
142 hedge funds and large institutions have $202M invested in Catalyst Pharmaceutical in 2020 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 42 increasing their positions, 47 reducing their positions, and 23 closing their positions.
178% more call options, than puts
Call options by funds: $827K | Put options by funds: $297K
17% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 23
3.05% more ownership
Funds ownership: 62.58% → 65.63% (+3.1%)
1% more funds holding
Funds holding: 140 → 142 (+2)
11% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 47
33% less capital invested
Capital invested by funds: $299M → $202M (-$97.2M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$14.9M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$5.57M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
+$4.01M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.74M |
| 5 |
RA
Royce & Associates
New York
|
+$1.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$5.34M |
| 2 |
NM
Newtyn Management
New York
|
-$4.62M |
| 3 |
PVI
Pura Vida Investments
New York
|
-$3.65M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.38M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
-$2.44M |
CPRX Hedge Fund Activity: Q3 2020 in Review
142 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2020, worth a combined $202M — down 33% from $299M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CPRX positions and 23 closed out — a net gain of 4 holders — while 42 added to existing stakes and 47 trimmed.
The largest buyer was Armistice Capital, adding an estimated $14.9M. The largest seller was Opaleye Management, exiting entirely with an estimated $5.34M sold.
- 142 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2020, up from 140 in Q2 2020.
- Funds reported $202M of Catalyst Pharmaceutical stock for Q3 2020, down 33% quarter-over-quarter.
- 27 funds opened new Catalyst Pharmaceutical positions in Q3 2020 and 23 closed out, a net change of +4 holders.
- The largest Catalyst Pharmaceutical buyer in Q3 2020 was Armistice Capital, an estimated $14.9M added.
- The largest Catalyst Pharmaceutical seller in Q3 2020 was Opaleye Management, an estimated $5.34M sold.
Based on aggregated 13F filings for Q3 2020.